Galanin(1-15)

Galanin exerts its effects not only as a full peptide but through active fragments, and galanin(1-15) has emerged as a functionally distinct N-terminal fragment with its own pharmacology. In anxiety and depression assays including the forced-swim, tail-suspension, open-field, and light-dark tests, galanin(1-15) induced strong depression-like and anxiogenic-like effects that were more pronounced than those of galanin itself; using a GalR2 antagonist and receptor-knockdown rats, investigators showed these actions depend on both GalR1 and GalR2, and proximity ligation assays suggested GalR1-GalR2 heteroreceptor complexes in the dorsal hippocampus and especially the dorsal raphe ^[1].

Counterintuitively, the same fragment can be harnessed to improve antidepressant therapy. Galanin(1-15) enhanced the behavioral antidepressant effect of fluoxetine in the forced-swim test, an interaction that required GalR1 and GalR2 and that engaged 5-HT1A receptors, since the 5-HT1A antagonist WAY100635 blocked it; mechanistically the combination altered the binding characteristics and messenger RNA of 5-HT1A receptors specifically in the dorsal hippocampus ^[2]. This positioned galanin(1-15) as a candidate co-treatment able to potentiate selective serotonin reuptake inhibitors.

The cognitive dimension is equally notable. In the novel object recognition task, galanin(1-15) reversed the memory impairment caused by fluoxetine while increasing 5-HT1A expression in the prefrontal cortex, with the GalR2 antagonist M871 blocking the behavioral effect, indicating that a GalR1-GalR2-5-HT1A heteroreceptor complex could counter an adverse cognitive effect of the antidepressant ^[3]. Reviews of 5-HT1A heteroreceptor complexes place galanin(1-15) among the receptor-receptor interactions offering new antidepressant targets ^[4]. Galanin(1-15) thus embodies a sophisticated, context-dependent pharmacology: intrinsically mood-worsening yet capable of enhancing and de-risking serotonergic antidepressants. It remains a preclinical research peptide.

Galanin(1-15) is a preclinical peptide with no human data. Its intrinsic anxiogenic and depression-like activity when given alone is a clear pharmacodynamic caution, since the fragment can worsen mood-related behavior in the absence of a co-administered antidepressant. Its therapeutic interest lies specifically in combination with serotonergic agents, a context that has only been explored in animals. No toxicology, pharmacokinetic, or human safety information exists, and it is not a consumer product.

Galanin(1-15) was characterized largely by the Malaga and Karolinska groups, with Millon, Diaz-Cabiale, Fuxe, and colleagues reporting its anxiogenic and depression-related profile in 2015 and its fluoxetine-enhancing and cognition-protective interactions in subsequent years. This work developed within the broader Fuxe framework of receptor-receptor interactions and heteroreceptor complexes, which reconceived neuropeptide fragments as modulators of monoaminergic signaling.

In neuropeptide and receptor-heteromer research galanin(1-15) is regarded as a compelling example of fragment-specific and complex-dependent pharmacology, and it is cited as a potential strategy to augment SSRIs while mitigating their cognitive side effects. It is a specialized academic concept rather than a developed therapeutic and is unknown in consumer and nootropic settings. It exists as a research peptide used to probe GalR1-GalR2-5-HT1A biology.